Public compound-province evidence data

41 names.
410 province routes.

One downloadable source map connecting compound identity, evidence lane, province-specific context, Health Canada product checks, provincial pharmacy verification, and the exact atlas section for every row.

A source-routing atlas, not a province-by-province legal verdict.Each row preserves the research, clinical-pipeline, or medicine identity and connects it to federal and provincial records. It does not certify a product, seller, shipment, prescription, compounding basis, medical use, or province-wide availability.
What this dataset adds

Compound identity joined to federal and provincial records.

Every row retains the query, bounded answer, primary identity source, Health Canada product database, province route, review date, and permanent atlas section.

01

Ten province routes

The dataset covers all Canadian provinces, from British Columbia and Ontario to Prince Edward Island and Newfoundland and Labrador.

02

41 identities

Research listings, investigational programs, and medicine records stay in separate evidence lanes even when search results combine them.

03

Every row is auditable

Open the human-readable atlas section, follow the official sources, or download the complete release for analysis and citation.

Human-readable province maps

Open any of the 41 compound atlases.

Each atlas contains 10 substantive province answers, official provincial routes, Health Canada product links, local guide handoffs, and the common identity source.

01FDA-reviewed unapproved peptide identity

KPV by province

Compare KPV across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

02US research-market identity

BPC-157 by province

Compare BPC-157 across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

03US research-market identity

TB-500 by province

Compare TB-500 across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

04US research-market identity

GHK-Cu by province

Compare GHK-Cu across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

05US research-market identity

Semax by province

Compare Semax across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

06US research-market identity

Melanotan II by province

Compare Melanotan II across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

07US research-market identity

MOTS-c by province

Compare MOTS-c across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

08US research-market identity with a separate FDA-licensed medicine record

Tesamorelin by province

Compare Tesamorelin across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

09US research-market identity with a failed oral obesity program and no FDA-approved drug

AOD-9604 by province

Compare AOD-9604 across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

10US research-market identity

Ipamorelin by province

Compare Ipamorelin across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

11US research-market identity

Selank by province

Compare Selank across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

12US research-market identity with a separate FDA-approved medicine record

PT-141 / Bremelanotide by province

Compare PT-141 / Bremelanotide across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

13US research-market identity

CJC-1295 no DAC by province

Compare CJC-1295 no DAC across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

14US research-market identity

CJC-1295 DAC by province

Compare CJC-1295 DAC across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

15Investigational clinical program

Retatrutide by province

Compare Retatrutide across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

16China-approved medicine and active clinical program

Mazdutide by province

Compare Mazdutide across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

17China-approved medicine and active development program

Ecnoglutide by province

Compare Ecnoglutide across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

18Investigational clinical program

Enicepatide by province

Compare Enicepatide across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

19Investigational clinical program

Eloralintide by province

Compare Eloralintide across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

20Investigational clinical program

Cagrilintide by province

Compare Cagrilintide across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

21Investigational clinical program

Petrelintide by province

Compare Petrelintide across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

22Investigational clinical program

CagriSema by province

Compare CagriSema across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

23Investigational clinical program

MariTide by province

Compare MariTide across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

24Investigational clinical program

Survodutide by province

Compare Survodutide across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

25Investigational clinical program

VK2735 by province

Compare VK2735 across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

26Investigational clinical program

Pemvidutide by province

Compare Pemvidutide across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

27Investigational clinical program

Amycretin / Zenagamtide by province

Compare Amycretin / Zenagamtide across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

28US FDA medicine reference

Tirzepatide by province

Compare Tirzepatide across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

29FDA-approved US medicine with country-specific status elsewhere

Orforglipron / Foundayo by province

Compare Orforglipron / Foundayo across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

30Product-specific approved medicine records in multiple jurisdictions

Semaglutide by province

Compare Semaglutide across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

31FDA-flagged unapproved research-market peptide identity

DSIP / Emideltide by province

Compare DSIP / Emideltide across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

32US research-market identity

IGF-1 LR3 by province

Compare IGF-1 LR3 across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

33US research-market identity

Kisspeptin-10 / KP-10 by province

Compare Kisspeptin-10 / KP-10 across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

34US research-market identity separated from SCENESSE

Melanotan I by province

Compare Melanotan I across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

35US research-market non-peptide coenzyme identity

NAD+ by province

Compare NAD+ across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

36US research-market identity with a withdrawn historical medicine record

Sermorelin by province

Compare Sermorelin across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

37No FDA-approved US product; exact foreign prescription products exist

Thymosin Alpha-1 by province

Compare Thymosin Alpha-1 across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

38FDA-approved US medicine with a withdrawn EU application

EGRIFTA WR by province

Compare EGRIFTA WR across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

39Product-specific FDA and EU medicine records

Liraglutide by province

Compare Liraglutide across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

40Product-specific FDA and EU medicine records

SCENESSE by province

Compare SCENESSE across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

41Product-specific FDA-approved US medicine record

VYLEESI by province

Compare VYLEESI across Canada's 10 provinces using official pharmacy routes, Health Canada product records, and bounded identity evidence.

Data dictionary

Definitions travel with the download.

The dictionary keeps identity, federal product checks, province verification, and the publication boundary explicit.

FieldDefinition
recordIdStable Peptide Local identifier for one compound and Canadian province verification row.
compoundResolved research-market, clinical-pipeline, or medicine identity used by the linked evidence record.
evidenceLaneThe evidence category for the resolved identity. Research listings, clinical programs, and medicine records are not interchangeable.
provinceDestination Canadian province whose official pharmacy or professional route is linked.
searchQueryPlain-language compound and province query represented by this row.
boundedAnswerEditorial routing answer that states what the identity, federal product record, and province record can and cannot establish.
identitySourceUrlPrimary source for the compound, medicine, or clinical-program identity.
provinceRecordUrlOfficial provincial pharmacy, professional, registration, or standards route.
productRecordUrlHealth Canada Drug Product Database used for the separate federal product check.
canonicalAtlasUrlCanonical Peptide Local atlas section for the exact compound and province row.
reviewedDateISO date when the compound-province source route was reviewed.
Use and citation

Link the dataset page or exact atlas section.

Cite this landing page for the full release. For one compound and province, cite the canonical atlas section so the bounded answer and source routes remain visible.

Corrections update the HTML atlas, CSV, and JSON from the same records. A row does not establish that a substance is legal, illegal, approved, unapproved, safe, unsafe, available, or suitable for an individual.

Compare the global 42-country dataset Open the Canada country guide Submit a correction